Neuro-Urology
- References
1. Cameron AP. Pharmacologic therapy for the neurogenic bladder. The Urologic clinics of North America. 2010;37(4):495.
2. Gajewski JB, Schurch B, Hamid R, Averbeck M, Sakakibara R, Agrò EF, et al. An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD). Neurourology and urodynamics. 2018;37(3):1152-1161.
3. Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. The Lancet Neurology. 2015;14(7):720-732.
4. Madersbacher H, Gajewski JB. Classification and Terminology of Neurogenic Lower Urinary Tract Dysfunction. In: Liao L, Madersbacher H, editors. Neurourology: Theory and Practice. Dordrecht: Springer Netherlands; 2019: 133-140.
5. Lose G, Griffiths D, Hosker G, Kulseng‐Hanssen S, Perucchini D, Schäfer W, et al. Standardisation of urethral pressure measurement: report from the Standardisation Sub‐Committee of the International Continence Society. Neurourology and Urodynamics: Official Journal of the International Continence Society. 2002;21(3):258-360.
6. De Wachter S. Ambulatory Urodynamics. In: Liao L, Madersbacher H, editors. Neurourology: Theory and Practice. Dordrecht: Springer Netherlands; 2019. p. 165-.
7. Andrea M Sartori , Thomas M Kessler , David M Castro-Díaz , Peter de Keijzer , Giulio Del Popolo, Hazel Ecclestone et al. Summary of the 2024 Update of the European Association of Urology Guidelines on Neurourology. Eur Urol 2024 Jun;85(6):543-555.
8. David A Ginsberg, Timothy B Boone, Anne P Cameron, Angelo Gousse, Melissa R Kaufman, Erick Keays , Michael J Kennelly. The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation. J Urol 2021 Nov;206(5):1097-1105.
9. Guyatt, G.H., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008. 336: 924.
10. Guyatt, G.H., et al. What is “quality of evidence” and why is it important to clinicians? BMJ, 2008. 336: 995.
11. Watanabe, T., et al. High incidence of occult neurogenic bladder dysfunction in neurologically intact patients with thoracolumbar spinal injuries. J Urol, 1998. 159: 965.
12. Cetinel, B., et al. Risk factors predicting upper urinary tract deterioration in patients with spinal cord injury: A retrospective study. Neurourol Urodyn, 2017. 36: 653.
13. Elmelund, M., et al. Renal deterioration after spinal cord injury is associated with length of detrusor contractions during cystometry-A study with a median of 41 years follow-up. Neurourol Urodyn, 2016.
14. Ineichen, B.V., et al. High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis. Multiple Sclerosis, 2017. 1352458517703801: 01.
15. Bors, E., et al. History and physical examination in neurological urology. J Urol, 1960. 83: 759.
16. Cameron, A.P., et al. The Severity of Bowel Dysfunction in Patients with Neurogenic Bladder. J Urol, 2015.
17. Vodusek, D.B. Lower urinary tract and sexual dysfunction in neurological patients. Eur Neurol, 2014. 72: 109.
18. Henze, T. Managing specific symptoms in people with multiple sclerosis. Int MS J, 2005. 12: 60.
19. Liu, C.W., et al. The relationship between bladder management and health-related quality of life in patients with spinal cord injury in the UK. Spinal Cord, 2010. 48: 319.
20. Bonniaud, V., et al. Development and validation of the short form of a urinary quality of life questionnaire: SF-Qualiveen. J Urol, 2008. 180: 2592.
21. Patel, D.P., et al. Patient reported outcomes measures in neurogenic bladder and bowel: A systematic review of the current literature. Neurourol Urodyn, 2016. 35: 8.
22. Best, K.L., et al. Identifying and classifying quality of life tools for neurogenic bladder function after spinal cord injury: A systematic review. J Spinal Cord Med, 2017. 40: 505.
23. Gulick, E.E. Bowel management related quality of life in people with multiple sclerosis: psychometric evaluation of the QoL-BM measure. Int J Nurs Stud, 2011. 48: 1066.
24. Schurch, B., et al. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil, 2007. 88: 646.
25. Foley, F.W., et al. The Multiple Sclerosis Intimacy and Sexuality Questionnaire -- re-validation and development of a 15-item version with a large US sample. Mult Scler, 2013. 19: 1197.
26. Sanders, A.S., et al. The Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 (MSISQ-19). Sex Disabil, 2000. 18: 3.
27. Linsenmeyer, T.A., et al. Accuracy of individuals with spinal cord injury at predicting urinary tract infections based on their symptoms. J Spinal Cord Med, 2003. 26: 352.
28. Massa, L.M., et al. Validity, accuracy, and predictive value of urinary tract infection signs and symptoms in individuals with spinal cord injury on intermittent catheterization. J Spinal Cord Med, 2009. 32: 568.
29. Husmann, D.A. Mortality following augmentation cystoplasty: A transitional urologist’s viewpoint. J Pediatr Urol, 2017.
30. Yang, C.C., et al. Bladder management in women with neurologic disabilities. Phys Med Rehabil Clin N Am, 2001. 12: 91.
31. Podnar, S., et al. Protocol for clinical neurophysiologic examination of the pelvic floor. Neurourol Urodyn, 2001. 20: 669.
32. Panicker, J.N., et al. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol, 2015. 14: 720.
33. Podnar, S., et al. Protocol for clinical neurophysiologic examination of the pelvic floor. Neurourol Urodyn, 2001. 20: 669.
34. Dangle, P.P., et al. Cystatin C-calculated Glomerular Filtration Rate-A Marker of Early Renal Dysfunction in Patients With Neuropathic Bladder. Urology, 2017. 100: 213.
35. Mingat, N., et al. Prospective study of methods of renal function evaluation in patients with neurogenic bladder dysfunction. Urology, 2013. 82: 1032.
36. Schafer, W., et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn, 2002. 21: 261.
37. Bellucci, C.H., et al. Neurogenic lower urinary tract dysfunction--do we need same session repeat urodynamic investigations? J Urol, 2012. 187: 1318.
38. McGuire, E.J., et al. Leak-point pressures. Urol Clin North Am, 1996. 23: 253.
39. Musco, S., et al. Value of urodynamic findings in predicting upper urinary tract damage in neurourological patients: A systematic review. Neurourol Urodyn, 2018.
40. Nosseir, M., et al. Clinical usefulness of urodynamic assessment for maintenance of bladder function in patients with spinal cord injury. Neurourol Urodyn, 2007. 26: 228.
41. Marks, B.K., et al. Videourodynamics: indications and technique. Urol Clin North Am, 2014. 41: 383
42. Bacsu, C.D., et al. Diagnosing detrusor sphincter dyssynergia in the neurological patient. BJU Int, 2012. 109 Suppl 3: 31.
43. Apostolidis, A., et al., Neurologic Urinary and Faecal Incontinence, In: Incontinence 6th Edition, P. Abrams, L. Cardozo, S. Khoury & A. Wein, Editors. 2017.
44. Barbalias, G.A., et al. Critical evaluation of the Crede maneuver: a urodynamic study of 207 patients. J Urol, 1983. 130: 720.
45. Reinberg, Y., et al. Renal rupture after the Crede maneuver. J Pediatr, 1994. 124: 279.
46. Wyndaele, J.J., et al. Neurologic urinary incontinence. Neurourol Urodyn, 2010. 29: 159.
47. Thomas, L.H., et al. Treatment of urinary incontinence after stroke in adults. Cochrane Database Syst Rev, 2008: CD004462.
48. Phe, V., et al. Management of neurogenic bladder in patients with multiple sclerosis. Nature Reviews Urology, 2016. 13: 275.
49. Madersbacher, H., et al. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord, 2013. 51: 432.
50. Madhuvrata, P., et al. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol, 2012. 62: 816.
51. Mehnert, U., et al. The management of urinary incontinence in the male neurological patient. Curr Opin Urol, 2014. 24: 586.
52. Stothers, L., et al. An integrative review of standardized clinical evaluation tool utilization in anticholinergic drug trials for neurogenic lower urinary tract dysfunction. Spinal Cord, 2016. 31: 31.
53. Bennett, N., et al. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol, 2004. 171: 749.
54. Horstmann, M., et al. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn, 2006. 25: 441.
55. Amend, B., et al. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol, 2008. 53: 1021.
56. Nardulli, R., et al. Combined antimuscarinics for treatment of neurogenic overactive bladder. Int J Immunopathol Pharmacol, 2012. 25: 35s.
57. Tijnagel, M.J., et al. Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin. BMC Urology, 2017. 17: 13.
58. Krhut, J., et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn, 2018. 37: 2226.
59. Welk, B., et al. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction. Neurourol Urodyn, 2018. 37: 2810.
60. Chen, S.F., et al. Therapeutic efficacy of low-dose (25mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. LUTS: Lower Urinary Tract Symptoms, 2018.
61. Peyronnet, B., et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort. Parkinsonism Rel Disord, 2018. 57: 22.
62. Zachariou, A., et al. Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron. Can J Urol, 2017. 24: 9107.
63. Abrams, P., et al. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol, 2003. 170: 1242.
64. Gomes, C.M., et al. Neurological status predicts response to alpha-blockers in men with voiding dysfunction and Parkinson’s disease. Clinics, 2014. 69: 817.
65. Moon, K.H., et al. A 12-week, open label, multi-center study to evaluate the clinical efficacy and safety of silodosin on voiding dysfunction in patients with neurogenic bladder. LUTS: Lower Urinary Tract Symptoms, 2015. 7: 27.
66. Guttmann, L., et al. The value of intermittent catheterisation in the early management of traumatic paraplegia and tetraplegia. Paraplegia, 1966. 4: 63.
67. Lapides, J., et al. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol, 1972. 107: 458.
68. Prieto, J., et al. Intermittent catheterisation for long-term bladder management. Cochrane Database Syst Rev, 2014: CD006008.
69. Prieto-Fingerhut, T., et al. A study comparing sterile and nonsterile urethral catheterization in patients with spinal cord injury. Rehabil Nurs, 1997. 22: 299.
70. Hollingsworth, J.M., et al. Determining the noninfectious complications of indwelling urethral catheters: a systematic review and meta-analysis. Ann Intern Med, 2013. 159: 401.
71. Bennett, C.J., et al. Comparison of bladder management complication outcomes in female spinal cord injury patients. J Urol, 1995. 153: 1458.
72. Larsen, L.D., et al. Retrospective analysis of urologic complications in male patients with spinal cord injury managed with and without indwelling urinary catheters. Urology, 1997. 50: 418.
73. Weld, K.J., et al. Effect of bladder management on urological complications in spinal cord injured patients. J Urol, 2000. 163: 768.
74. Lavelle, R.S., et al. Quality of life after suprapubic catheter placement in patients with neurogenic bladder conditions. Neurourol Urodyn, 2016. 35: 831.
75. Del Popolo, G., et al. Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. Eur Urol, 2008. 53: 1013.
76. Yuan, H., et al. Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis. Int Neurourol J, 2017. 21: 53.
77. Cheng, T., et al. Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One, 2016. 11: e0159307.
78. Wagle Shukla, A., et al. Botulinum Toxin Therapy for Parkinson’s Disease. Seminars in Neurology, 2017. 37: 193.
79. Grosse, J., et al. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol, 2005. 47: 653.
80. Rovner, E., et al. Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment. J Urol, 2016.
81. Ni, J., et al. Is repeat Botulinum Toxin A injection valuable for neurogenic detrusor overactivity-A systematic review and meta-analysis. Neurourol Urodyn, 2018. 37: 542.
82. Michel, F., et al. Botulinum toxin type A injection after failure of augmentation enterocystoplasty performed for neurogenic detrusor overactivity: preliminary results of a salvage strategy. The ENTEROTOX study. Urology, 2019.
83. Stöhrer, M., et al. Diagnosis and treatment of bladder dysfunction in spinal cord injury patients. Eur Urol Update Series 1994. 3: 170
84. Derry, F., et al. Audit of bladder neck resection in spinal cord injured patients. Spinal Cord, 1998. 36: 345.
85. Perkash, I. Use of contact laser crystal tip firing Nd:YAG to relieve urinary outflow obstruction in male neurogenic bladder patients. J Clin Laser Med Surg, 1998. 16: 33.
86. Dykstra, D.D., et al. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a doubleblind study. Arch Phys Med Rehabil, 1990. 71: 24.
87. Schurch, B., et al. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol, 1996. 155: 1023.
88. Huang, M., et al. Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia. J Rehabil Med, 2016. 48: 683.
89. Utomo, E., et al. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction. Cochrane Database Syst Rev, 2014. 5: CD004927.
90. Barthold, J.S., et al. Results of the rectus fascial sling and wrap procedures for the treatment of neurogenic sphincteric incontinence. J Urol, 1999. 161: 272.
91. Gormley, E.A., et al. Pubovaginal slings for the management of urinary incontinence in female adolescents. J Urol, 1994. 152: 822.
92. Kakizaki, H., et al. Fascial sling for the management of urinary incontinence due to sphincter incompetence. J Urol, 1995. 153: 644.
93. Mingin, G.C., et al. The rectus myofascial wrap in the management of urethral sphincter incompetence. BJU Int, 2002. 90: 550.
94. Abdul-Rahman, A., et al. Long-term outcome of tension-free vaginal tape for treating stress incontinence in women with neuropathic bladders. BJU Int, 2010. 106: 827.
95. Losco, G.S., et al. Long-term outcome of transobturator tape (TOT) for treatment of stress urinary incontinence in females with neuropathic bladders. Spinal Cord, 2015. 53: 544.
96. El-Azab, A.S., et al. Midurethral slings versus the standard pubovaginal slings for women with neurogenic stress urinary incontinence. Int Urogynecol J, 2015. 26: 427.
97. Light, J.K., et al. Use of the artificial urinary sphincter in spinal cord injury patients. J Urol, 1983. 130: 1127.
98. Farag, F., et al. Surgical treatment of neurogenic stress urinary incontinence: A systematic review of quality assessment and surgical outcomes. Neurourol Urodyn, 2016. 35: 21.
99. Kim, S.P., et al. Long-term durability and functional outcomes among patients with artificial urinary sphincters: a 10-year retrospective review from the University of Michigan. J Urol, 2008. 179: 1912.
100. Vainrib, M., et al. Differences in urodynamic study variables in adult patients with neurogenic bladder and myelomeningocele before and after augmentation enterocystoplasty. Neurourol Urodyn, 2013. 32: 250.
101. Krebs, J., et al. Functional outcome of supratrigonal cystectomy and augmentation ileocystoplasty in adult patients with refractory neurogenic lower urinary tract dysfunction. Neurourol Urodyn, 2016.
102. Hoen, L., et al. Long-term effectiveness and complication rates of bladder augmentation in patients with neurogenic bladder dysfunction: A systematic review. Neurourol Urodyn, 2017. 07: 07.
103. Myers, J.B., et al. The effects of augmentation cystoplasty and botulinum toxin injection on patient reported bladder function and quality of life among individuals with spinal cord injury performing clean intermittent catheterization. Neurourol Urodyn, 2019. 38: 285.
104. Mitsui, T., et al. Preoperative renal scar as a risk factor of postoperative metabolic acidosis following ileocystoplasty in patients with neurogenic bladder. Spinal Cord, 2014. 52: 292.
105. Moreno, J.G., et al. Improved quality of life and sexuality with continent urinary diversion in quadriplegic women with umbilical stoma. Arch Phys Med Rehabil, 1995. 76: 758.
106. Phe, V., et al. Continent catheterizable tubes/stomas in adult neuro-urological patients: A systematic review. Neurourol Urodyn, 2017.
107. Sakhri, R., et al. [Laparoscopic cystectomy and ileal conduit urinary diversion for neurogenic bladders and related conditions. Morbidity and better quality of life]. Prog Urol, 2015. 25: 342.
108. Bakke, A., et al. Bacteriuria in patients treated with clean intermittent catheterization. Scand J Infect Dis, 1991. 23: 577.
109. Nicolle, L.E., et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis, 2005. 40: 643.
110. Goetz, L.L., et al. International Spinal Cord Injury Urinary Tract Infection Basic Data Set. Spinal Cord, 2013. 51: 700.
111. Everaert, K., et al. Urinary tract infections in spinal cord injury: prevention and treatment guidelines. Acta Clin Belg, 2009. 64: 335.
112. Lee, B.S., et al. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev, 2012. 10: CD003265.
113. Hachen, H.J. Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial. J Urol, 1990. 143: 759.
114. Rees, P.M., et al. Sexual function in men and women with neurological disorders. Lancet, 2007. 369:512.
115. Lombardi, G., et al. Management of sexual dysfunction due to central nervous system disorders: a systematic review. BJU Int, 2015. 115 Suppl 6: 47.
116. Chen, L., et al. Phosphodiesterase 5 Inhibitors for the Treatment of Erectile Dysfunction: A Trade-off Network Meta-analysis. Eur Urol, 2015. 68: 674.
117. Lombardi, G., et al. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature. J Sex Med, 2012. 9: 970.
118. Bella, A.J., et al. Intracavernous pharmacotherapy for erectile dysfunction. Endocrine, 2004. 23: 149.
119. Kapoor, V.K., et al. Intracavernous papaverine for impotence in spinal cord injured patients. Paraplegia, 1993. 31: 675.
120. Vidal, J., et al. Intracavernous pharmacotherapy for management of erectile dysfunction in multiple sclerosis patients. Rev Neurol, 1995. 23: 269.
121. Gross, A.J., et al. Penile prostheses in paraplegic men. Br J Urol, 1996. 78: 262.
122. Kimoto, Y., et al. Penile prostheses for the management of the neuropathic bladder and sexual dysfunction in spinal cord injury patients: long term follow up. Paraplegia, 1994. 32: 336.
123. Kolettis, P.N., et al. Fertility outcomes after electroejaculation in men with spinal cord injury. Fertil Steril, 2002. 78: 429.
124. Chehensse, C., et al. The spinal control of ejaculation revisited: a systematic review and metaanalysis of anejaculation in spinal cord injured patients. Hum Reprod Update, 2013. 19: 507.
125. Beretta, G., et al. Reproductive aspects in spinal cord injured males. Paraplegia, 1989. 27: 113.
126. Brackett, N.L., et al. Application of 2 vibrators salvages ejaculatory failures to 1 vibrator during penile vibratory stimulation in men with spinal cord injuries. J Urol, 2007. 177: 660.
127. Westgren, N., et al. Sexuality in women with traumatic spinal cord injury. Acta Obstet Gynecol Scand, 1997. 76: 977.
128. Fruhauf, S., et al. Efficacy of psychological interventions for sexual dysfunction: a systematic review and meta-analysis. Arch Sex Behav, 2013. 42: 915.
129. Przydacz, M., et al. Recommendations for urological follow-up of patients with neurogenic bladder secondary to spinal cord injury. Int Urol Nephrol, 2018. 50: 1005.
130. Abrams, P., et al. A proposed guideline for the urological management of patients with spinal cord injury. BJU Int, 2008. 101: 989.
131. B. Blok (Chair) DC-D, G. Del Popolo JG, R. Hamid, G. Karsenty, T.M. Kessler, (Vice-chair) JP, Guidelines Associates: H. Ecclestone SM, B. Padilla-Fernández AS, L.A. ‘t Hoen. EAU guidelines on Neuro-Urology. EAU extended guidelines. 2020; 2020:53